Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

by Jay Achar, Cathy Hewison, Ana P. Cavalheiro et al.
Emerging Infectious Diseases, Vol. 23, No. 10, October 2017

3 pp. 346 kB
https://wwwnc.cdc.gov/eid/article/23/10/pdfs/17-0303.pdf

The authors describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. They report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

(Visited 4 times, 1 visits today)
This entry was posted in Essential Medicines, General, Maternal & Child Health, Tuberculosis. Bookmark the permalink.